Compare American Superconductor Corporation (AMSC) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Superconductor Corporation vs Inovio Pharmaceuticals Inc — how do they compare? American Superconductor Corporation trades at $35.49 (market cap $1.74B), while Inovio Pharmaceuticals Inc trades at $1.2 (market cap $97.91M). The key difference: American Superconductor Corporation is far larger — about 17.8× Inovio Pharmaceuticals Inc's market cap, and American Superconductor Corporation is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMSC | INO | |
|---|---|---|
Market Cap | $1.74B | $97.91M |
Sector | Technology | Health |
52-Week High | $66.68 | $2.87 |
52-Week Low | $25.95 | $1.05 |
Enterprise Value | $1.61B | $68.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
INO trades at $1.18, down 0.84% with bearish technical signals. The company shows minimal revenue of $65K against massive losses, with a net margin of -130,000% and negative cash flow. Recent news highlights an active FDA review for INO-3107 with an October 2026 decision date, while multiple law firms investigate potential fiduciary breaches by directors.
The investment case hinges on the binary FDA approval of INO-3107. While analyst consensus is 53% buy-rated, fundamental metrics are deeply negative. Key risks include clinical trial outcomes, cash burn, and legal scrutiny. Upside depends entirely on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
